| Literature DB >> 33738088 |
Mahsa Nouri Barkestani1, Sina Naserian1,2,3, Georges Uzan1,4, Sara Shamdani1,3.
Abstract
Due to the current lack of innovative and effective therapeutic approaches, tissue engineering (TE) has attracted much attention during the last decades providing new hopes for the treatment of several degenerative disorders. Tissue engineering is a complex procedure, which includes processes of decellularization and recellularization of biological tissues or functionalization of artificial scaffolds by active cells. In this review, we have first discussed those conventional steps, which have led to great advancements during the last several years. Moreover, we have paid special attention to the new methods of post-decellularization that can significantly ameliorate the efficiency of decellularized cartilage extracellular matrix (ECM) for the treatment of osteoarthritis (OA). We propose a series of post-decellularization procedures to overcome the current shortcomings such as low mechanical strength and poor bioactivity to improve decellularized ECM scaffold towards much more efficient and higher integration.Entities:
Keywords: Cartilage tissue engineering; decellularized extracellular matrix; osteoarthritis; post-decellularization
Year: 2021 PMID: 33738088 PMCID: PMC7934046 DOI: 10.1177/2041731420983562
Source DB: PubMed Journal: J Tissue Eng ISSN: 2041-7314 Impact factor: 7.813
Figure 1.Summary of ECM based tissue engineering procedure. This figure depicts the succession of different steps including the origin of ECM, decellularization methods, and their efficacy assessment; post-decellularization methods, and finally recellularization factor that are essential in an appropriate ECM-based tissue engineering procedure.
Timeline of decellularization techniques progression during years.
| Years | Tissue origin | Description |
|---|---|---|
| 1948 | Muscle samples | Pulverization of tissue samples and preparing acellular homogenates of though tissues.[ |
| 1975 | Bovine blood vessel | Solubilizing blood vessels with 4% SD.[ |
| Rabbit/rat renal tubules | Solubilizing renal tubules with 4% SD.[ | |
| 1980 | Rat liver | Long-term Culture of normal rat hepatocytes on decellularized rat liver ECM.[ |
| 1995 | Porcine-SIS | Using an acellular porcine-SIS, as temporary bioscaffold for treating Achilles tendon defect in the dog. SIS remodeled neotendon and after 8 weeks became degraded.[ |
| 1996 | Cadaveric allograft skin | Acellular allograft dermal matrix used as scaffold and grafted to the excised wound base. After 14 days, neovascularization, neoepithelialization and infiltration were observed.[ |
| 1999 | Cultured BCE-cells and PF-HR9 endodermal cells | Produce decellularized ECMs by culturing BCE and PF-HR9 endodermal cells. ECM coating on plastic surface was uniform and suitable for HS703T human colon carcinoma cells attachment and spreading.[ |
| 2000 | Human and sheep pulmonary valves | Human and sheep pulmonary valves decellularization using the SynerGraft treatment process and implantation in the right ventricular outflow tract of growing sheep. Human pulmonary valves were implanted in human. They became recellularized with recipient cells without provoking antibody response.[ |
| 2001 | Porcine aortic valves | Porcine aortic valves recellularization by human neonatal fibroblasts cells in a novel bioreactor resulted in a heart valve populated with viable human cells.[ |
| 2004 | Porcine dermal matrix | Decellularization of the porcine dermal matrix using trypsin and SDS. Cell component was completely removed.[ |
| 2004 | Peripheral nerve tissue | Decellularization of peripheral nerve tissue with Triton X-200, sulfobetaine-10/16 was suited for studying specific aspect of nerve regeneration.[ |
| 2005 | Bovine pericardium | Decellularization of the bovine pericardium with triton-x, SD, SDS, and PLA2, which resulted in removal of xenogeneic antigens.[ |
| 2005 | Porcine small bowel | Decellularization of porcine small bowel segments using mechanical, chemical and enzymatic methods. Implantation of tissue in a porcine model after recellularization and vascularization.[ |
| 2006 | Human placenta | Decellularization of human placenta ECM through perfusion via the existing vasculature. An intact vascular network of ECM architecture was preserved.[ |
| 2007 | Chicken tendon | Combining decellularization and chemical oxidation to decellularize chicken Tendon.[ |
| Bone marrow cell-derived ECM | Culturing MSCs on bone marrow cell-derived ECM which perfectly promoted replication and expansion of MSCs.[ | |
| 2008 | Porcine urinary bladder | Enzymatic solubilization of porcine urinary bladder to prepare an Injectable gel form of ECM for culturing smooth muscle cells.[ |
| Rat heart | Rat heart decellularization by coronary detergent perfusion to preserve an acellular and intact matrix with perfusable vascular architecture. Recellularization with cardiac or endothelial cells.[ | |
| 2009 | Yorkshire boar Trachea tubular | Yorkshire boar Trachea tubular decellularization using detergent-enzymatic method and implantation into mice. It was mechanically and structurally comparable to the native ECM with no immune response in animal models.[ |
| Porcine cornea | Decellularization of porcine cornea by ultrahigh hydrostatic pressure method and implantation into rabbit that was successfully a possible corneal scaffold for an artificial cornea.[ | |
| 2010 | Rat liver | Generation of a transplantable rat liver graft by decellularization via portal perfusion with SDS and recellularization of liver matrix with adult hepatocytes.[ |
| 2013 | Pig and human | Decellularization of pig and human trachea-lung using freezing and SDS washes. Recellularization of scaffold with human adult primary alveolar epithelial type II cells supported cell attachment and cell viability.[ |
| Human kidney | Decellularization of human kidney with SDS in order to obtain human renal ECM scaffold.[ | |
| 2014 | Heart, cartilage and adipose cell-laden ECM | Using decellularized heart, cartilage and adipose cell-laden ECM as a bioink for 3D printing scaffold.[ |
| Tumor tissues | Decellularization of tumor tissues for modeling tumor microenvironment. A549 human pulmonary adenocarcinoma cells implanted into mice were used for decellularization.[ | |
| Human and rat whole-lung | Decellularization of human and rat whole-lung scaffold by perfusion with SDS and recellularization with iPSCs.[ | |
| 2015 | Rat and human lungs | Decellularization of rat and human lungs and Repopulating vascular compartment for regeneration of functional pulmonary vasculature.[ |
| 2015 | Human liver | Decellularization of human liver and repopulation with human hepatic stellate cells (LX2), hepatocellular carcinoma (Sk-Hep-1) and hepatoblastoma (HepG2).[ |
| 2016 | Human heart | Human heart perfusion-decellularization and recellularization with myocytes derived from human iPSCs.[ |
| 2017 | Cardiac tissue | Cardiac tissue regeneration using hCPCs cell-laden dECM bioinks for 3D printing scaffold. Stem cell patch induced vascularization and tissue matrix formation in vivo.[ |
| 2018 | Human brain | Human brain dECM 3D hydrogel facilitates the direct conversion of fibroblasts into induced neuronal cells.[ |
| 2020 | Human liver | Revascularization of decellularized liver scaffold with human umbilical vein endothelial cells HUVECs using perfusion bioreactor culture and implanation into pig.[ |
SD: sodium deoxycholate; ECM: extracellular matrix; SIS: small intestinal submucosa; BCE: bovine corneal endothelial-cell; SDS: sodium dodecyl sulfate, PLA: poly-L-lactic acid; iPSCs: induced pluripotent stem cells; 3D: three dimension; hCPCs: human cardiac progenitor cells; dECM: decellularized ECM.
Methods of tissue, organ, and cell-derived ECM decellularization.
| Techniques | Agents | Advantage | Disadvantage | Organ Decellularization | Ref |
|---|---|---|---|---|---|
| 1.Chemical | • Peracetic acid | • Disrupting nucleic acids | • Damage the ECM microarchitecture | SIS, urinary bladder | Syed et al.[ |
| 1.2 Alkaline base | • Sodium hydroxide | • Destroy cellular and nuclear components | • Eliminate growth factors | Kidney | Zambon et al.[ |
| 1.3 Alcohol | • Ethanol | • Disinfectant agent | Change the collagen 3D structure by crosslinking the ECM | Adipose tissue and cornea | Flynn[ |
| 1.4 Chelating agents | • EDTA | • Undermine cell adhesion | Undermine cell adhesion causing cell and ECM dissociation | Heart, kidney, liver, and pancreas | Seo et al.,[ |
| 1.5 Detergents | I. Ionic detergents | • Disrupts the lipid and protein interactions | Removes GAGs, GFs, and ECM proteins | Porcine cornea, myocardium, heart valve/small intestine, kidney, human vein, heart, kidney, porcine, human lungs | Pang et al.,[ |
| • SD | • Denatures the protein interaction | Agglutination of DNA on the tissue’s surface | Blood vessels, tracheas, diaphragm, aortic root, and small intestines | Syed et al.,[ | |
| • Sodium | • Short elution time | • Causing dehydration | Porcine corneal stromal | Dong et al.[ | |
| II. Zwitterionic detergents | • Intermediate potency | • Useful for thin tissues | Human and porcine lung, Oesophagus | Gilpin et al.,[ | |
| III. Non-ionic detergents | • Denature the protein interactions | • Less ECM disruption than SDS | Fibrosis, livers, kidneys and aortic valves | Zambon et al.,[ | |
| • Trypsin | • Disrupts the DNA, protein and interactions | • Low potency | Dermis, cartilage, cornea porcine pulmonary valves, heart valve, trachea | Zhou et al.,[ | |
| 2. Enzymatic | • Nucleases | • Digest and eliminate cellular and nuclear materials | • Not effective alone | Human lung, porcine heart valves, and kidney | Wagner et al.,[ |
| • Lipase | • Catalyze the hydrolysis of cell lipids and phospholipids | • Depletes GAG content | Human amniotic membrane | Shi et al.[ | |
| 3. Physical | • Disrupt cellular membrane | • Insufficient removal of genetic materials lead to immune rejection | Fibroblast cell sheet | Xing et al.[ | |
| 3.2 Emersion/agitation | • Used when the access to the vasculature is difficult Facilitates cellular content removal | • Excessive agitation can disrupt ECM | Heart valves, skeletal muscle, urinary bladder, peripheral nerves, skin, cartilage | Tudorache et al.,[ | |
| 3.3 Perfusion | • Infusion of agents through the organ vasculature | • Inappropriate perfusion pressures can disrupt ECM Optimization is required for each tissue/organ | Heart, lung, liver, kidney, and pancreas | Zambon et al.,[ | |
| 3.4 Pressure gradient | • Denatures cells with pressure | • Disrupt the ECM ultrastructure | Whole organs and porcine blood vessel | Crapo et al.,[ | |
| 3.5 HHP | • Short treatment time | Limited efficacy with small probe | Liver, lung, cornea and blood vessels | Funamoto et al.[ | |
| 3.6 Non-thermal electroporation | NA | • Substantial removal of volatile substances | Cornea | Hashimoto et al.[ | |
| 3.7 Super critical CO2 | • Non-toxic and non-flammable | • NA | Adipose tissue, aorta and heart ECM hydrogel | Wang et al.,[ | |
ECM: extracellular matrix; SIS: small intestine submucosa; EDTA: ethylene diamine tetra acetic acid; EGTA: ethylene glycol-bis (β-amino ethyl ether)-N,N,N′,N′-tetra-acetic acid; 3D: tridimensional, SDS: sodium dodecyl sulfate; SD: sodium deoxycholate; CHAPS: 3-[(3-cholamidopropyl) dimethyl ammonia]-1-propane sulfonate; GAG: glycosaminoglycan; GFs: growth factors; HHP: high hydrostatic pressure; NA: not available.
Figure 2.Summary of extracellular matrix decellularization procedures. Articular cartilage obtained from the animal knee is first decellularized. Acellular ECM maintains the structural and chemical integrity of the original tissue. Afterwards, the acquired dECM is used as a scaffold to reproduce a functional articular cartilage tissue by introducing different cell types, notably mesenchymal stem cells. The final engineered tissue can be transplanted into the knee joint of the OA patient.
Articular Cartilage decellularization and recellularization protocols. The efficacy of cell removal, preservation of biochemical components, and mechanical properties has been evaluated by attributing the following scores: (++++) very effective, (+++) effective, (++) intermediate effective and (+) low effective.
| ECM origin | Decellularization protocol | Cell removal | ECM biochemical component | ECM mechanical properties | Recellularization protocol | Result | Ref |
|---|---|---|---|---|---|---|---|
| Porcine articular cartilage | Chemical and enzyme treatment, Freeze-thaw | + + + + | + + + | + + + | • hTMSCs | • Supported chondrogenesis differentiation and cell viability | Pati et al.[ |
| Porcine CMS | Carbon dioxide laser technique | + + + + | + + | + + + | • Rabbit-derived chondrocytes | • Formed cartilage-like tissue in vitro | Li et al.[ |
| hBMSC-derived ECM | Triton X-100 | + + | + + + + | + + + | • Human chondrocyte | • Increased proliferation, chondrogenic differentiation, and chondrocytic phenotype | Yang et al.[ |
| Porcine knee articular cartilage | Physical pulverization |
|
|
| • Rabbit ACs or ASCs | • Enhanced chondrogenic phenotypes without exogenous growth factors | Yin et al.[ |
| Porcine articular cartilage | Freeze-thaw cycles | + + + | + + | + | • Porcine synovium-derived MSCs | • Seeded cells infiltrated into the cartilage deep zone after 28 days | Bautista et al.[ |
| Bovine articular cartilage | Freeze-thaw cycles | + + | + + | + + | • Bovine chondrocytes | • Most of the cellular material was removed | Antons et al.[ |
| Porcine articular cartilage | Deionized water or SDS | + + + | + | + + | • Human MSCs | • Complete removal of cells | Shen et al.[ |
| Bovine cartilage | Freeze-thaw | + + | + + | + + | • Human MSCs | • Pepsin-digestion provided medium supplement or 3Dhydrogels but did not promote differentiation | Rothrauff et al.[ |
| Human cartilage | Physical pulverization | + | + + | + + | • Rabbit ADSCs | • Rabbit knees defects were filled 100% mostly with hyaline cartilage | Kang et al.[ |
| Goat knee joint cartilage | Physical pulverization | + + + + | + + | + + | • Rat BMSCs | • Chondrogenic differentiated after 21 days without the use of exogenous growth factors | Yin et al.[ |
ECM: extracellular matrix; HCL: hydrochloride; hTMSCs: human turbinate mesenchymal stromal cells; MEM: minimum essential medium; SDS: sodium dodecyl sulfate; CMS: cartilage matrix scaffold; hBMSC: human bone marrow stem cell; SCID: severe combined immunodeficiency; GAGs: glycosaminoglycans; ACs: articular chondrocytes; ASCs: adipose-derived stem cells; MSCs: mesenchymal stem cells; DMEM: Dulbecco’s modified Eagle’s medium; ADSCs: adipose-derived stem cells; TGF-β: transforming growth factor beta 1.
FDA-approved and commercially available devices for OA treatment. This table describes the advantages, disadvantages and applications of different devices, scaffolds and injectable solutions for OA treatment. CS: chondroitin sulfate; AC: articular cartilage; OA: osteoarthritis; HA: hyaluronic acid; ACI: autologous chondrocyte implantation; MSCs: mesenchymal stem cells.
| Device type | Trade name | Company | Components | Device indication to use | Advantage | Disadvantage | Ref |
|---|---|---|---|---|---|---|---|
| GENVISC 850, HYMOVIS[ | Orthogenrx INC, Fidia Farmaceutici | HA | Pain relief in knee OA | Doros et al.[ | |||
| Natural | TRILURON™[ | Fidia Farmaceutici S.p.A. | Sodium hyaluronate | Pain relief in knee OA | • Absorbable | • Low mechanical stability | Berenbaum et al.[ |
| TriVisc[ | OrthogenRx, Inc. | Sodium hyaluronate | Supplement the viscous fluid in the knee and relieve knee pain due to OA | Becker et al.[ | |||
| CaReS | Arthro Kinetics | Collagen type I gel matrix | Chondral knee defects | Roessler et al.[ | |||
| Natural | Chondro-Gide | Geistlich | Bilayer | Scaffold-associated | • Biocompatible | • Low mechanical stability | Steinwachs et al.[ |
| DeNovo®NT | Zimmer | Juvenile cartilaginous allograft tissue | AC repair and cartilage restoration. | Yanke et al.[ | |||
| ChondroGide | Geistlich | Porcine Collagen bilayer I/III | Cartilage regeneration with a smooth, compact top layer, and a rough, porous bottom layer | Haddo et al.[ | |||
| HyloFast | Anika | Single 3D fibrous layer | Entraps MSCs to arthroscopically treat chondral and osteochondral lesions | Gobbi et al.[ | |||
| Natural non-injectable scaffold + cells | NeoCart | Histogenix | ACI on 3D Collagen scaffold | Rebuild knee cartilage | • Biodegradable | • Not easy available | DeBerardino[ |
| Hyaff-11 | Fida advanced biopolymer | ACI on HA based polymer scaffold | Chondral knee defects | Turner et al.[ | |||
| Maci[ | Vericel Corporation | ACI porcine collagen scaffold | Repair of symptomatic, full-thickness cartilage defects of the knee in adult patients | Nixon et al.[ | |||
| Novocart 3D | Tetec | ACI on Collagen—CS Scaffold | Treatment of chondral knee defects | Zak et al.[ | |||
| Chondron | Sewon CellOnTech | Autologous chondrocyte implantations | Chondral knee defects | Choi et al.[ | |||
| Carticel | Genzyme | Expanded chondrocytes from patient’s knee | Repair of symptomatic cartilage defects of the femoral condyle, caused by acute or repetitive trauma | Manfredini et al.[ | |||
| Synthetic injectable scaffolds | Augment Bone Graft[ | Biomimetic therapeutics, LLC | Beta-Tricalcium Phosphate + bovine collagen + human platelet-derived growth factor | Alternative autograft in arthrodesis of the ankle and hind foot due to OA | • Easily handled | • Low chondrogenisity | Solchaga et al.[ |
| Synthetic non-injectable scaffolds | R3 delta ceramic hip system | SMITH & NEPHEW, INC. | Ceramic-on-ceramic hip prosthesis | Use in skeletally mature patients requiring primary total hip arthroplasty due to non-inflammatory OA | Lee et al.[ | ||
| Cartiva® | Cartiva, Inc. | Polyvinyl alcohol and saline synthetic implant | Treatment of patients with degenerative or post-traumatic OA | Chang et al.[ | |||
| Synthetic non-injectable scaffolds + cells | BioSeed-C | Biotissue | ACI on 3D synthetic polymer scaffold | AC defects treatment in the knee | Kreuz et al.[ |
FDA-approved devices.
Figure 3.Cartilage tissue engineering process. In the first step, cartilage ECM is selected from different sources such as cartilage tissue or cell-culture-derived ECM. Thereafter, the decellularization process is performed to remove cells and their genetic materials. (a) dECM content is mixed with cross-linking agents, (b) polymers, (c) polymers via cross-linking agents, (d) cell encapsulated injectable hydrogel microparticles, and (e) platelet-rich plasma. After the post-decellularization procedures, cells are implanted into the final scaffold in a recellularization process. In the end, the cartilage tissue engineering product is ready for application.